Innovent Biologics Presents Promising Data for Obesity and Metabolic Therapies

Innovent Biologics shared new clinical and preclinical findings for its pipeline of obesity and metabolic disease treatments. Data included results for mazdutide in adults and adolescents, alongside early-stage findings for several next-generation oral and injectable therapies. Preclinical studies for one oral GLP-1 receptor agonist showed significant weight loss in animal models, indicating strong potential.